Cyteir Therapeutics, Inc.
Cyteir Therapeutics, Inc. is grouped at the issuer level across 1 linked ticker lifecycle, combining public listing, delisting, source, and shareholder outcome records from the archive.
Lifecycle Map
Issuer enters the archive
May 28, 2021Cyteir Therapeutics, Inc. is represented as an issuer-level entity with 1 linked public-market ticker lifecycle.
Delisting event
Mar 18, 2024SEC 25 delisting filing recorded for baseline coverage.
SourceC1662244 stopped trading
Mar 18, 2024C1662244 is linked to Cyteir Therapeutics, Inc. and ended with final status "private".
Source
Entity Graph
Cyteir Therapeutics, Inc.issuedC1662244
C1662244listed onOTHER
C1662244resulted inunknown
Source-Backed Claims
- Cyteir Therapeutics, Inc. held a Special Meeting of Stockholders on November 16, 2023, at 3:00 p.m. Eastern Time, to consider dissolution and liquidation of the Company.DEFM14A
- The record date for voting at the Special Meeting was October 5, 2023.DEFM14A
- The estimated distribution to stockholders based on the Plan of Dissolution is between approximately $106 million and $121 million, equating to approximately $2.92 to $3.31 per share of common stock.DEFM14A
- Cyteir's Board of Directors unanimously approved the Plan of Dissolution on September 7, 2023.DEFM14A
- Proxy materials regarding the Special Meeting were mailed to stockholders on or about October 12, 2023.DEFM14A
- The Plan of Dissolution allows for the liquidation and distribution of remaining assets to stockholders following Board approval.DEFM14A
- If the Dissolution Proposal is approved, the final record date for stockholder interests will coincide with the filing of the Certificate of Dissolution with the Delaware Secretary of State.DEFM14A
- A contingency reserve of approximately $500,000 will be established to satisfy contingent and unknown liabilities during the liquidation process.DEFM14A
Associated Tickers
Public-market security lifecycles tied to this issuer record.